Skip to main content

New Survey Reveals Hidden Impact of Pulmonary Fibrosis as Charity Calls for Updated National ILD Standards

Category

The Pulmonary Fibrosis Trust has called on NHS England to finalise and publish updated national standards for specialist interstitial lung disease (ILD) services after new patient evidence highlighted the significant physical, emotional and practical impact of pulmonary fibrosis on patients and families.

The call was made during the Trust's first Westminster briefing, hosted by Jim Shannon MP, where parliamentarians heard evidence from patients, clinicians and researchers about the challenges facing people living with pulmonary fibrosis and other ILDs.
Central to the briefing were findings from the Trust's 2025-26 patient and carer survey, which gathered 517 responses and more than 4,000 individual answers. Patients described delayed or missed diagnoses, inconsistent information, difficulties obtaining the right referrals and long gaps between specialist reviews.

The survey found:

  • 70.5% reported anxiety, depression or isolation
  • More than six in ten required help with at least one activity of daily living
  • 43.6% reported financial impacts related to their condition
  • 75.2% said oxygen restricted travel and social participation
  • More than a third had considered stopping treatment because of medication-related difficulties

The charity says the findings demonstrate the need for a clear, measurable and consistently delivered national pathway for diagnosis, treatment and ongoing support.

MPs attending the briefing were asked to support the publication of updated national ILD standards, question ministers about implementation and examine access to specialist respiratory services within their constituencies.

The briefing also heard from Professor Peter George, Consultant Respiratory Physician and Clinical Lead for the Interstitial Lung Disease Unit at Royal Brompton Hospital, who outlined findings from a recent study published in Thorax suggesting ILD is substantially more common than previously recognised.

The research estimates that approximately 200,000 people are living with ILD in the UK and around 60,000 new cases are diagnosed annually. Researchers concluded that ILD should no longer be considered a rare disease and called for increased resources and service planning to meet growing demand.

Alongside the clinical and policy evidence, MPs heard about the lived experience of patients including Katie, a 38-year-old from South East London living with interstitial lung disease with autoimmune features who now requires oxygen when walking.
Jim Shannon MP, Chair of the APPG for Respiratory Health, said:

"Pulmonary fibrosis is recognised within NHS respiratory disease strategies and long-term conditions programmes but, unlike cancer or COPD, there is no dedicated national pulmonary fibrosis strategy for England.

As a consequence, at the moment we see delayed diagnosis, with many patients experiencing symptoms for months or years before referral; variation in access to specialist ILD services across regions; and a growing demand on services as the UK population ages and awareness improves.

The All-Party Parliamentary Group for Respiratory Health has been pressing for some time for a National Action Plan, or a similar dedicated policy strategy for respiratory health, and there is no doubt that the lives of pulmonary fibrosis patients would benefit from this."

Peter Bryce, Chairman of the Pulmonary Fibrosis Trust, said:

"Patients are telling us that pulmonary fibrosis affects every aspect of their lives, from their mental wellbeing and family relationships to their ability to work, travel and remain independent.

The experiences shared through our survey show why updated national standards are urgently needed and why patients and carers must be placed at the heart of future service planning.

We need consistent pathways for diagnosis, treatment and ongoing support so that every patient can access high-quality specialist care, regardless of where they live."